What does Montagu Newhall Associates invest in?
Montagu Newhall Associates invests most often at Series C and Series D (65% of the rounds on record).
Montagu Newhall Associates highlights
- 01
17 rounds on record
- 02
Mostly Series C and Series D: 65% of its rounds
- 03
Sole investor in 1 rounds, median $7.7M
- 04
8 exits from the portfolio
What they do
- Type
- Growth equity (from a list, unverified)
- Cheque size
- Not stated
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first17 appearances
- 2009
1 round
- Mar
- 2008
3 rounds
- Dec
- Jun
- May
- 2007
4 rounds
- Aug
- Jul
- Jun
- May
- 2006
3 rounds
- Nov
- Jul
- Mar
- 2005
1 round
- Mar
- 2004
1 round
- Jul
- 2003
2 rounds
- Nov
- Nov
- 2002
1 round
- Aug
- 2001
1 round
- Aug
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
Exits from the portfolio
Companies it backed that were later bought or listed8 in all
Zonare Medical SystemsBought by Mindray Medical International$105MJun 2013
ExactTargetBought by Salesforce$2.5BJun 2013
ExactTargetListedUndisclosedMar 2012
GenVaultBought by IntegenXUndisclosedFeb 2011
Vurv TechnologyBought by Taleo$129MMay 2008
MyogenBought by Gilead SciencesUndisclosedOct 2006
Proxima TherapeuticsBought by Cytyc$160MMar 2005
An exit counts when it came after the firm's first round in the company. From historical deal records.